The FDA Approved List Explained: What Providers Must Know About Biologics in 2026

Introduction: The Question Every Provider Should Be Asking

The single most dangerous assumption in regenerative medicine today is that “FDA registered” means “FDA approved.” Most providers cannot tell the difference, and this confusion carries significant consequences.

Misclassifying a biologic product exposes providers to FDA warning letters, product seizures, civil or criminal enforcement, state medical board discipline, and malpractice liability. The regulatory framework for biologics is genuinely complex, and the industry has not done providers any favors by obscuring these distinctions.

This article serves as a practical framework to help providers understand where products actually fall on the FDA regulatory spectrum, audit their current supply chain, and recognize what a truly compliant distributor relationship looks like.

The scale of the problem is substantial. An estimated 2,750 U.S. stem cell clinics were offering unapproved injections as of 2021, and research found that 96% of clinic websites displayed at least one misstatement about regulatory status. When providers search for an FDA approved list, what they find rarely tells them what they most urgently need to know.

What the FDA Approved List Actually Covers

There is no single “FDA approved list” for all biologics. Approval status depends on product category, regulatory pathway, and intended use, making the concept of a universal list misleading.

What does exist: FDA’s Center for Biologics Evaluation and Research (CBER) maintains lists of approved cell and gene therapies, licensed biologics, and RMAT-designated products that have reached marketing approval. As of 2025, more than 40 cell and gene therapies have received FDA approval, spanning CAR-T cell therapies, AAV gene therapies, lentiviral gene therapies, and CRISPR-based therapies.

Seven FDA-approved CAR-T cell therapies target cancers including acute lymphoblastic leukemia, large B-cell lymphoma, and multiple myeloma. These products legitimately appear on an FDA approved list.

The critical gap lies elsewhere. The biologics most commonly used in orthopedic, regenerative, and wellness clinics (exosomes, amniotic products, umbilical cord-derived products, PRP, and BMAC) are largely absent from this list. There are currently zero FDA-approved exosome products for any medical use, and the FDA has issued multiple warning letters to companies marketing exosome products as regenerative therapies.

PRP is not FDA-approved as a drug or biologic for therapeutic use. The FDA regulates the centrifuge devices used to prepare it as 510(k)-cleared medical devices, while PRP itself generally does not require premarket drug approval under the autologous, minimally manipulated framework.

The FDA’s Tiered Regulatory Framework for Biologics: 361 vs. 351

The FDA regulates Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) under 21 CFR Part 1271, creating two primary regulatory lanes that form the legal backbone every provider must understand.

Section 361 HCT/Ps: The Lower-Risk Lane

Section 361 products are HCT/Ps that meet four specific criteria and are therefore regulated primarily for communicable disease prevention. No premarket approval is required.

The four criteria are: (1) minimal manipulation, (2) homologous use, (3) no systemic effect unless autologous or for close relatives, and (4) not combined with non-exempt articles. All four criteria must be met. Failing even one automatically reclassifies the product as a Section 351 biologic.

Practical examples of products that legitimately operate under Section 361 include allograft bone, certain amniotic membrane allografts used for wound coverage (homologous use), and autologous PRP. The August 2025 FDA Tissue Reference Group recognition of five BioLab Holdings amniotic membrane allograft products as HCT/Ps validates their regulatory pathway, though this recognition is not drug approval.

Section 351 Biologics: The High-Approval Lane

Section 351 products are biologics that fail one or more of the Section 361 criteria and therefore require a full Biologics License Application (BLA) and clinical trials.

This pathway applies to FDA-approved cell and gene therapies: CAR-T products, AAV gene therapies, CRISPR therapies, and RMAT-designated products that have completed clinical development.

The Regenerative Medicine Advanced Therapy (RMAT) designation, created by the 21st Century Cures Act in 2016, is designed to accelerate development, not bypass approval. As of September 2025, the FDA had received nearly 370 RMAT designation requests, approved 184 designations, but only 13 had reached full marketing approval.

In December 2025, the FDA approved Waskyra (etuvetidigene autotemcel) for Wiskott-Aldrich syndrome. In January 2026, the FDA granted RMAT designation to NouvNeu001, an iPSC-derived cell therapy for Parkinson’s disease.

The Most Dangerous Misconception: Registration Is Not Approval

FDA establishment registration under 21 CFR Part 1271 is not the same as FDA approval. Registration is a 45-minute online process that notifies the FDA of a manufacturer’s location and product list. The FDA reviews and approves nothing through this process alone.

The FDA’s own guidance states: “FDA acceptance of an establishment registration does NOT constitute a determination that the establishment is in compliance or that the HCT/P is licensed or approved.”

This misconception is actively exploited. Manufacturers and distributors use phrases like “FDA registered facility,” “FDA compliant,” and “FDA regulated product” in ways that imply approval without stating it.

The 2025 enforcement wave demonstrates the consequences. The FDA issued warning letters to BioStem Technologies (January 2025), New Life Medical Services (September 2025), and BioXtek LLC (December 2025) for marketing unapproved human umbilical cord-derived and amniotic products without BLAs.

In October 2025, the U.S. Supreme Court declined to reconsider the FDA’s authority to regulate unproven stem cell therapies, cementing the regulatory landscape.

How to Audit Your Current Biologic Supply Chain

Providers can apply this framework immediately to evaluate their current product relationships.

Step 1: Identify the Regulatory Classification Claim. Does the manufacturer or distributor explicitly state whether the product is a Section 361 HCT/P or a Section 351 biologic? Vague language like “FDA registered” or “FDA compliant” without specifying the regulatory pathway is a red flag.

Step 2: Evaluate the Four Section 361 Criteria. Exosome products almost universally fail the minimal manipulation and homologous use criteria, making them Section 351 biologics. If a product’s marketing claims describe systemic effects, disease treatment, or uses beyond the tissue’s normal function, the product is almost certainly operating outside its legitimate Section 361 classification.

Step 3: Request Manufacturer Documentation. Providers should obtain current establishment registration confirmation, donor eligibility procedures, CGTP compliance documentation, and any FDA correspondence including warning letters.

Step 4: Evaluate the Distributor’s Role. A compliant distributor should vet manufacturer compliance on the provider’s behalf, maintain current knowledge of FDA enforcement trends, and proactively remove non-compliant products from their catalog.

What a Truly Compliant Distributor Relationship Looks Like

A compliance-first distributor relationship includes proactive manufacturer vetting, transparent regulatory classification, active enforcement monitoring, clinical documentation support, and education and compliance training.

Matrix Biologics has built its Integrated Safety Intelligence™ (ISI) platform specifically to address these requirements. The platform includes FDA-approved AI software integration, safety and risk profiling, regulatory pathway alignment tools, clinical protocol support, consent workflow management, and real-world outcomes tracking.

The Matrix-Accredited sourcing standards provide expert-led, compliance-driven product validation that vets manufacturers against 21 CFR Part 1271 requirements before products reach the provider.

Conclusion: The FDA Approved List Is a Starting Point, Not a Safety Net

The FDA approved list tells providers which products have completed the most rigorous regulatory pathway. It does not tell them whether the products they are currently using are compliant, safe, or legally defensible.

FDA registration is not FDA approval. A manufacturer’s establishment registration tells the FDA where they are and what they sell. It tells providers nothing about whether the FDA has reviewed or approved the product.

As the regenerative medicine market approaches $61 billion by 2035 and the FDA’s enforcement posture continues to tighten, the providers who will thrive are those who build their practices on compliant infrastructure from the beginning.

Ready to Audit Your Biologic Supply Chain?

Providers seeking a supply chain compliance review can connect with Matrix Biologics at their Scottsdale office: Raintree Corporate Center, 15333 N. Pima Road, Suite #305, Scottsdale, AZ 85260, or by calling 602-480-0486.

At Matrix Biologics, the mission extends beyond supplying products. The company builds the compliance infrastructure that lets providers practice regenerative medicine with confidence, clarity, and integrity.